11月21日，百洋医药跌2.65%，成交额8034.22万元。两融数据显示，当日百洋医药获融资买入额604.20 万元，融资偿还1512.56万元，融资净买入-908.36万元。截至11月21日，百洋医药融资融券余额合计 4.68亿元。 融资方面，百洋医药当日融资买入604.20万元。当前融资余额4.67亿元，占流通市值的4.03%，融资余 额超过近一年70%分位水平，处于较高位。 分红方面，百洋医药A股上市后累计派现15.51亿元。近三年，累计派现12.01亿元。 机构持仓方面，截止2025年9月30日，百洋医药十大流通股东中，香港中央结算有限公司位居第十大流 通股东，持股290.97万股，为新进股东。工银前沿医疗股票A（001717）退出十大流通股东之列。 责任编辑：小浪快报 融券方面，百洋医药11月21日融券偿还300.00股，融券卖出500.00股，按当日收盘价计算，卖出金额 1.10万元；融券余量3.61万股，融券余额79.71万元，超过近一年50%分位水平，处于较高位。 资料显示，青岛百洋医药股份有限公司位于山东省青岛市市北区开封路88号，成立日期2005年3月8日， 上市日期2021年6月30日 ...

长江商报消息 ●长江商报记者 潘瑞冬 "投资孵化+商业化"双轮驱动的百洋医药（301015.SZ）继续布局创新器械。 11月29日晚间，百洋医药发布公告称，公司全资子公司百洋健康产业国际商贸有限公司旗下的河北百洋 萨普医疗设备科技有限公司（下称"百洋萨普"）将引入Zap Therapeutic的490万美元增资。这是百洋医药 布局创新器械领域的进一步动作。 长江商报记者注意到，在产业布局的同时，百洋医药还在加码投资孵化。公司持有华昊中天、北海康成 股票，2025年第三季度，百洋医药的公允价值变动收益接近1亿元，驱动第三季度归母净利润由降转 增。 加快放射外科机器人本土化生产 据悉，Zap Therapeutic为百洋医药间接参股公司Zap Medical System,Ltd.的全资子公司，且百洋医药高级 管理人员王廷伟担任Zap Medical System,Ltd.董事，因此本次交易构成关联交易。公告显示，Zap Therapeutic注册于中国香港，成立于2017年6月，主营业务为持股投资。 公司表示，若还原两票制业务后计算，报告期公司实现营业收入65.05亿元。对于净利润下滑，公司表 示，公司压缩了批 ...

Core Insights - Baiyang Pharmaceutical's subsidiary, Baiyang Health Industry International Trade Co., Ltd., is set to introduce a $4.9 million capital increase from Zap Therapeutic, raising the registered capital of Baiyang Sap Medical Equipment Technology Co., Ltd. from $5.1 million to $10 million, while maintaining a 51% ownership stake [1] - This capital increase is part of Baiyang Pharmaceutical's ongoing strategy to expand its presence in the innovative medical device sector, particularly focusing on the ZAP-X robotic system for radiation surgery [1][2] - The ZAP-X robot has been clinically validated and has completed over 5,000 treatments globally, showcasing its precision and non-invasive advantages in treating complex brain diseases [1][2] Company Developments - Baiyang Sap was established to enhance the production capacity of the ZAP-X system and support its commercialization in China, aiming to create a local production base for radiation therapy equipment [2] - The partnership with Zap Therapeutic is expected to leverage combined resources in funding, technology, and market channels, facilitating the localization of ZAP-X production and expediting its clinical integration [2] - Baiyang Pharmaceutical has signed a cooperation agreement with Peking University International Hospital to establish a precision radiation therapy center, focusing on innovative treatment solutions for brain tumors using the ZAP-X system [3] Financial Performance - In the first three quarters of the year, Baiyang Pharmaceutical reported revenues of 5.627 billion yuan and a net profit of 476 million yuan, indicating a strong performance driven by a dual strategy of investment and commercialization [3]

Mergers and Acquisitions - Chenyi Intelligent plans to acquire 55% of Huaze Electronics through cash payment [1] - Beijiete's wholly-owned subsidiary intends to acquire 55% of Dahao Mining for 225 million yuan [1] Share Buybacks and Equity Transfers - Chenzhan Optoelectronics' controlling shareholder is transferring 5.02% of shares [2] - Huamin Co., Ltd. plans to transfer 5.17% of shares by Jianxianghuihong [2] - Pro Pharmaceutical intends to repurchase shares worth between 180 million to 360 million yuan, with a maximum price of 23 yuan per share [2] - Ganyue Expressway's actual controller will change from the Provincial Department of Transportation to the Provincial State-owned Assets Supervision and Administration Commission [2] External Investments and Daily Operations - Hefei China has completed its suspension review and resumed trading [3] - Dwei Co., Ltd. is advancing the procedures for lithium battery new energy projects in Hunan Chenzhou [4] - Desay SV plans to launch an AI computing terminal for the robotics sector [4] - Neusoft Group received a notification from a major domestic automotive manufacturer to supply intelligent cockpit domain controllers, with a total expected supply amount of 4.2 billion yuan [4] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision, acquiring 60% ownership post-investment [5] - Dongfang Electric intends to invest 910 million yuan to hold 49% in a joint venture [6] - Bailian Group's subsidiary plans to transfer 100% of its stake in Yangpu Century Bailian for 78.286 million yuan [6] - Ruisheng Intelligent's subsidiary won a bid for a China Mobile ICT project, focusing on computing server hardware and systems [6] - Zhifei Biological's clinical trial application for the ZFA01 adjuvant vaccine has been accepted [7] - Haizheng Pharmaceutical's subsidiary is collaborating with East China Institute on a biomanufacturing project for heparin [8] - Baiyang Pharmaceutical's Zap Therapeutic plans to invest 4.9 million USD in Baiyang Sap to expedite the clinical introduction of the ZAP-X Mars surgical robot [8] - Jinbei Automotive plans to invest 5.8 billion yuan and purchase equity in Changchun Zhongtuo Molding Technology [9] - Baili Tianheng has secured a commitment from Bank of China Sichuan Branch for a total of no less than 8 billion yuan in comprehensive credit support [10]

Group 1 - The core point of the announcement is that Baiyang Pharmaceutical plans to introduce Zap Therapeutic Solutions Limited to invest $4.9 million in Baiyang Sap Medical Equipment Technology Co., Ltd. to enhance its capital strength and meet operational development needs [1][2] - Baiyang Sap is a wholly-owned subsidiary of Baiyang Health Industry International Trade Co., Ltd., which is fully owned by Baiyang Pharmaceutical [1] - The investment aims to support the localization of the ZAP-X radiotherapy robot, enhancing production capacity and facilitating the commercialization of ZAP-X in clinical settings [2] Group 2 - Baiyang Pharmaceutical intends to expand its product layout in the innovative medical device sector and promote resource integration and collaborative development through investments in Zap Medical System, Ltd. starting from July 2024 [2] - The collaboration will include exclusive commercialization and manufacturing services for ZAP-X, which is expected to enrich the company's industrial layout in innovative devices and increase revenue and profitability from innovative products [2]

格隆汇11月19日丨百洋医药(301015.SZ)公布，为满足河北百洋萨普医疗设备科技有限公司（简称"百洋 萨普"）的经营发展需求，增强其资本实力，百洋萨普拟引入ZapTherapeuticSolutionsLimited（简 称"ZapTherapeutic"）增资490万美元。百洋萨普系青岛百洋医药股份有限公司全资子公司百洋健康产业 国际商贸有限公司（简称"百洋健康"）持股100%的公司，百洋健康放弃本次增资的优先认缴出资权。 本次增资完成后，百洋萨普的注册资本将由510万美元增加至1,000万美元，百洋健康的持股比例将下降 至51%，本次交易不会导致公司合并报表范围变更。ZapTherapeutic为ZapMedicalSystem,Ltd.的全资子公 司，ZapMedicalSystem,Ltd.为公司间接参股的公司且公司高级管理人员王廷伟担任其董事。根据《深圳 证券交易所创业板股票上市规则》相关规定及实质重于形式的原则，公司认定ZapTherapeutic为公司的 关联方，本次交易构成关联交易。 ...

格隆汇11月19日丨百洋医药(301015.SZ)公布，为满足河北百洋萨普医疗设备科技有限公司（简称"百洋 萨普"）的经营发展需求，增强其资本实力，百洋萨普拟引入ZapTherapeuticSolutionsLimited（简 称"ZapTherapeutic"）增资490万美元。百洋萨普系青岛百洋医药股份有限公司全资子公司百洋健康产业 国际商贸有限公司（简称"百洋健康"）持股100%的公司，百洋健康放弃本次增资的优先认缴出资权。 本次增资完成后，百洋萨普的注册资本将由510万美元增加至1,000万美元，百洋健康的持股比例将下降 至51%，本次交易不会导致公司合并报表范围变更。ZapTherapeutic为ZapMedicalSystem,Ltd.的全资子公 司，ZapMedicalSystem,Ltd.为公司间接参股的公司且公司高级管理人员王廷伟担任其董事。根据《深圳 证券交易所创业板股票上市规则》相关规定及实质重于形式的原则，公司认定ZapTherapeutic为公司的 关联方，本次交易构成关联交易。 ...

2024年1至12月份，百洋医药的营业收入构成为：药品和医疗器械等销售占比92.5%，品牌服务占比 7.18%，其他业务占比0.32%。 每经AI快讯，百洋医药（SZ 301015，收盘价：22.68元）11月19日晚间发布公告称，公司第四届第三次 董事会会议于2025年11月19日以现场结合通讯的方式召开。会议审议了《关于关联方向全资子公司增资 暨关联交易的议案》等文件。 每经头条（nbdtoutiao）——爱泼斯坦案文件解密倒计时，美国会"秒过"法案直通特朗普，引爆两党"极 限撕扯" 截至发稿，百洋医药市值为119亿元。 （记者 张明双） ...

百洋医药11月19日公告，公司全资子公司百洋健康产业国际商贸有限公司的全资子公司河北百洋萨普医 疗设备科技有限公司拟引入Zap Therapeutic增资490万美元。增资完成后，百洋萨普注册资本将增至 1,000万美元，百洋健康的持股比例下降至51%。为拓展公司在创新器械领域的产品布局，自2024年7月 公司陆续对ZapMedicalSystem,Ltd.进行产业投资，并针对其旗下核心产品ZAP-X火星舟放射外科机器人 开展独家商业化合作、制造服务等一系列合作。本次Zap Therapeutic向百洋萨普增资，能够充分整合双 方的资金、技术、市场渠道等多方面资源优势，有利于推动ZAP-X的本土化生产，助力ZAP-X快速导入 临床场景。 ...

为满足河北百洋萨普医疗设备科技有限公司（以下简称"百洋萨普"）的经 营发展需求，增强其资本实力，百洋萨普拟引入 Zap Therapeutic Solutions Limited （以下简称"Zap Therapeutic"）增资 490 万美元。百洋萨普系青岛百洋医药股份 有限公司（以下简称"公司"）全资子公司百洋健康产业国际商贸有限公司（以 下简称"百洋健康"）持股 100%的公司，百洋健康放弃本次增资的优先认缴出资 权。本次增资完成后，百洋萨普的注册资本将由 510 万美元增加至 1,000 万美元， 百洋健康的持股比例将下降至 51%，本次交易不会导致公司合并报表范围变更。 东兴证券股份有限公司 关于青岛百洋医药股份有限公司 关联方向全资子公司增资暨关联交易的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐人"）作为青岛百 洋医药股份有限公司（以下简称"百洋医药"或"公司"）2021 年度首次公开发 行股票和 2023 年度向不特定对象发行可转换公司债券持续督导的保荐人，根据 《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 ...